INTRODUCTION
============

Several oncogenic mutations in non-small cell lung cancer (NSCLC) have been discovered, directly impacting patient\'s prognosis and management. With the exception of well-known alterations, such as epidermal growth factor receptor (*EGFR*) mutation or anaplastic lymphoma kinase (*ALK*) rearrangement, genetic profiling has identified additional driver mutations in lung adenocarcinomas with 9%--14% being new targetable oncogenes.[@B1]

Human epidermal growth factor receptor 2 (*HER2*) is a member of the *ERBB* receptor tyrosine kinase family. *HER2* receptor is activated by homodimerization or heterodimerization with the other *ERBB* family receptors, especially *EGFR*,[@B1] resulting in augmentation of *EGFR* signaling. Oncogenic activation of *HER2* is present in various malignancies, such as breast, ovarian, bladder, salivary gland, endometrial, pancreatic, and NSCLC.[@B2] The major mechanisms of *HER2* alterations in NSCLC include *HER2* protein overexpression, gene amplification and mutation.[@B3] *HER2* mutation is predominantly observed in female patients, non-smokers and patients with adenocarcinoma subtype, similar to *EGFR*-mutated NSCLC.[@B4]

The benefit of *HER2*-targeted therapy for NSCLC harboring *HER2* alteration is much less defined than that for breast cancer. Trastuzumab, a monoclonal antibody that targets extracellular domain IV of *HER2* receptor, has not shown a clear benefit in *HER2*-positive NSCLC.[@B5] By comparison, tyrosine kinase inhibitors (TKIs) that target both *EGFR* and *HER2* have been associated with response to treatment.[@B5] Among them, afatinib (Gilotrif^®^, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA) is a potent and irreversible *ERBB* family blocker with preclinical activity in *Ba/F3* cells expressing an artificial *HER2* mutant and in a human lung cancer cell line with an insertional mutation at codon 776.[@B6] Results with afatinib in *HER2*-positive NSCLC have been promising, but there have been only a few clinical studies and limited data in the form of case reports involving western patients.[@B7][@B8][@B9][@B10][@B11]

We present the first oriental case of previously treated NSCLC, which initially had no available activating target and finally had response to afatinib after detection of *HER2* mutation. Furthermore, we review the clinical impacts of *HER2* alterations in diagnosis and the role of afatinib in treatment of NSCLC harboring *HER2* mutation.

CASE DESCRIPTION
================

A 50-year-old Korean woman who had never smoked visited our lung cancer clinic in February 2015. She complained of upper airway infection symptoms of mild back pain followed by cough with sputum and rhinorrhea. Computed tomography (CT) from an outside hospital showed a right upper lobar mass with enlargement of adjacent interlobar lymph node, and miliary distribution of multiple tiny nodules in both lungs ([Fig. 1A](#F1){ref-type="fig"}). She was diagnosed with stage IV lung adenocarcinoma with metastases to both lungs, T12 spine, left femur and brain that was proven by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), positron emission tomography and brain magnetic resonance imaging (MRI). Her initial tumor biopsy from primary mass and lymph nodes was negative for *EGFR* mutation and *ALK* translocation.

![Serial CT scans of a present patient before treatment with afatinib. (**A**) Baseline image before chemotherapy. (**B**) Post-treatment image after four cycles of pemetrexed and cisplatin, assessed as stable disease. (**C**) Follow-up image without subsequent treatment before start of gefitinib, showing disease progression of right upper lobe mass and lung-to-lung metastases. (**D**) Post-treatment image after two cycles of gefitinib, assessed as progression with aggravation of lung-to-lung metastases.\
CT = computed tomography.](jkms-33-e7-g001){#F1}

She received four cycles of pemetrexed and cisplatin, and her tumor burden was retained as stable disease ([Fig. 1B](#F1){ref-type="fig"}). She stopped the chemotherapy due to poor performance status without maintenance therapy. Upon progression of right upper lobar mass, multiple lung nodules and metastatic lymphadenopathies after 2 months without subsequent treatment ([Fig. 1C](#F1){ref-type="fig"}), she received gefitinib for the next 2 months. Subjectively-rated symptoms of nausea and myalgia seemed to ease, but gefitinib was finally stopped due to aggravation of gastrointestinal toxicity and lung-to-lung metastases ([Fig. 1D](#F1){ref-type="fig"}). Thereafter, progression in brain metastasis was also demonstrated in follow-up MRI. She suffered from general weakness, nausea and back pain, and so was reluctant to receive further cytotoxic chemotherapy.

In September 2015, she agreed to be tested for another activating mutation using previously achieved specimen by EBUS-TBNA. Pathologic examination revealed a poorly differentiated atypical cell nest with focal glandular differentiation ([Fig. 2B](#F2){ref-type="fig"}). Immunohistochemical stain for *c-erbB2* showed weak membranous staining ([Fig. 2C](#F2){ref-type="fig"}). After direct sequencing as screening test, the following next generation sequencing (NGS) of the tissue revealed a *HER2* exon 20 mutation with A-to-G base change at nucleotide 2437 (c.2437A\>G), which led to substitution of aspartate for asparagine at position 813 (p.N813D) ([Fig. 2A](#F2){ref-type="fig"}). This mutation has never been reported. In October 2015, she started afatinib 40 mg daily. An initial clinical and radiologic response was achieved within a month. She professed a sense of well-being and relief of back pain, and simple chest X-ray showed more decreased lung nodules grossly. During week 6 of treatment, a CT assessment revealed a partial response in extracranial lesions with prominent regression of primary lung tumors in the right upper lobe and lung-to-lung metastases ([Fig. 3](#F3){ref-type="fig"}). Brain metastases had maintained the stable state, and she did not complain of any neurologic symptom or sign. After stepwise dose reduction to 20 mg due to stomatitis and nausea, she has continued the medication until February 2016 without deterioration of subjective symptom and tumor burden. Last CT scan on January 2016 still showed a partial response in extracranial lesion, but brain MRI revealed mild increase of metastases. At last visit on February 2016, the patient complained of general weakness and anorexia with stomatitis, and thereafter she was lost to follow-up.

![Pathologic and molecular diagnosis for lung adenocarcinoma harboring *HER2* mutation. (**A**) Next-generation sequencing result of a patient with *HER2* exon 20 mutation. The A-to-G base-pair change at nucleotide 2437 in *HER2* exon 20 (c.2437A\>G) is denoted by the dominant black bar which is found in approximately 6% of sequence reads. The sequence depth is 2614 indicated by the blue line. The A-to-G base change leads to substitution of aspartate for asparagine at position 813 (p.N813D). Variation less than 1% is regarded as experimental noise. Nucleotides are colored as follows: G as black bar, A as green bar, C as blue bar, T as red bar, and base deletion as gray bar. A selection of aligned sequence reads is shown with A-to-G base change highlighted in yellow with red lettering. First line shows the reference sequence (green). (**B**) Poorly differentiated atypical cell nest with focal glandular differentiation (H & E, × 400). (**C**) Weak membranous staining on immunohistochemical staining for *c-erbB2* (× 400).\
*HER2* = human epidermal growth factor receptor 2, H & E = haematoxylin and eosin, NGS = next generation sequencing.](jkms-33-e7-g002){#F2}

![Radiologic findings before and after treatment. (**A**) Chest X-ray before starting afatinib. (**B**) X-ray 6 weeks after afatinib. (**C**) CT scan before starting afatinib. (**D**) CT scan 6 weeks after afatinib. The images demonstrate regression of right upper lung mass and lung-to-lung metastases.\
CT = computed tomography.](jkms-33-e7-g003){#F3}

DISCUSSION
==========

We provide evidence of clinical benefit from treatment with afatinib in an oriental patient with *HER2*-mutant NSCLC who had previously failed cytotoxic chemotherapy and treatment with reversible *EGFR* inhibitor.

In terms of *HER2* gene mutation, NGS is becoming an important method of detection in NSCLC, even though the traditional single-gene sequencing (i.e., Sanger sequencing) is still widely performed. NGS can simultaneously test for multiple oncogenic driver mutations, rearrangements and gene amplifications.[@B5] In this case, we performed direct sequencing for screening followed by NGS for confirmation. And we found a *HER2* exon 20 mutation (p.N813D) which has never been reported. Although it takes more than three weeks to confirm the result and the cost is quite high in real clinic settings, NGS has advantage over direct sequencing in detecting very rare mutations even when the biopsy specimen is limited.

There were some reports about types of *HER2* mutation. Compared with *EGFR*, *HER2* mutations were less heterogeneous. The majority (over 80%) were in-frame insertions in exon 20 of the kinase domain, which ranged from 3 to 12 base-pair (bp), all nested between codons 775 and 831.[@B12] The 12-bp insertion is known as the most common mutation showing duplication/insertion of 4 amino acids (YVMA) at codon 775 (A775_G776insYVMA).[@B12] In addition, other mutations are as follows: bp insertion (i.e., G776\>VC, P780_Y781insGSP, V777_G778insCG), insertion/deletion (i.e., M774delinsWLV, G776\>LC), or point mutations (i.e., L755S, G776C, G776L, V777L).[@B7][@B9][@B12][@B13] There was no previous report about N813D point mutation found in this case. N813D mutation is also located in exon 20 of *HER2* kinase domain. Given that most *HER2* mutations were known to be found in the proximal region of exon 20, N813D is supposed to be a novel and rare mutation in the distal region of exon 20.

Available data concerning *HER2*-targeted therapy for *HER2*-positive NSCLC is insufficient and less defined. Trastuzumab monotherapy or addition to chemotherapy has not shown a clear benefit in *HER2*-positive NSCLC,[@B5] although certain cases with favorable outcome have been described.[@B9][@B14] Several dual TKIs to *EGFR* and *HER2* have shown hopeful results in select patients. In a recent phase II cohort study for recurrent or newly detected lung adenocarcinoma, dacomitinib produced objective responses in patients with specific *HER2* exon 20 insertion mutation (response rate 12%, median overall survival 9 months).[@B13] Neratinib in combination with temsirolimus also showed responses in two of 11 patients with *HER2* mutation-positive NSCLC in a phase I study of pretreated patients with *HER2*-driven cancers.[@B15]

The National Comprehensive Cancer Network has included trastuzumab and afatinib as potential therapy options for NSCLC patients with *HER2* mutations.[@B16] Afatinib, a pan-*HER* inhibitor, has shown limited but promising data for treatment of *HER2*-mutated NSCLC from several reports and studies mostly involving western patients, including Europe, United States, and Australia. In an exploratory phase II study with afatinib, all three patients with *HER2* mutation showed objective response, even after failure of other *EGFR*- and/or *HER2*-targeted treatment.[@B7] In a recent case report, a patient harboring specific *HER2* mutated lung adenocarcinoma with exon 20 YVMA insertion (p.A775_G776insYVMA) showed durable response for 10 months to afatinib; the patient had been alternately treated with cytotoxic chemotherapy and *HER2*-targeted agents including pertuzumab and trastuzumab.[@B8] A retrospective series of 16 patients with *HER2* mutation showed favorable outcomes, with a 93% disease control rate for trastuzumab-based therapies and 100% for afatinib.[@B9] In a recent phase II study of afatinib for previously treated lung adenocarcinoma, five of seven patients achieved disease control (71%). Furthermore, one patient who received afatinib (40 mg/day) combined with paclitaxel following afatinib monotherapy (50 mg/day) due to progression showed a confirmed partial response with a duration of 41.9 weeks.[@B11] These data demonstrate that afatinib may have clinical application in patients whose tumors are constitutively dependent on the *HER2* pathway. Similarly, in the present report, which is the first case in an eastern population, the patient showed a rapid regression within a month and durable response over 5 months. Although dose reduction was inevitable due to adverse events beginning a month after commencement of treatment, the objective response was continued thereafter even when the initial dose of afatinib was halved (20 mg/day).

The antitumor mechanism of afatinib in *HER2*-altered NSCLC has been demonstrated by in vitro and in vivo experimental study. In a study using *HER2*-altered NSCLC cell lines and xenograft mouse model, afatinib downregulated the phosphorylation of *HER2* and *EGFR* in addition to their downstream signaling, and induced and antiproliferative effect through G1 arrest and apoptotic cell death both in *HER2*-amplified and -mutant cell lines, which was also confirmed in vivo.[@B17]

However, the superiority of a *HER2*-targeted therapy to chemotherapy is not conclusive. In a European cohort study for advanced NSCLC with *HER2* exon 20 insertion mutation, subgroup with conventional therapy including chemotherapy and reversible *EGFR*-TKI did not show a survival benefit compared to those with *HER2*-targeted drugs including trastuzumab (monotherapy or addition to chemotherapy), trastuzumab emtasine (T-DM1), neratinib, afatinib and lapatinib.[@B10] Therefore, additional well-designed randomized clinical trials with novel and target-specific agents are warranted.

In summary, afatinib could be a potential treatment option for subgroups of *HER2*-mutated NSCLC that progress after previous cytotoxic chemotherapy or treatment with reversible *EGFR*-TKIs. NGS could be advantageous as it provides a precise result for *HER2* mutation, even in limited biopsy specimen.

We used afatinib off-label in this case because the drug was approved only for 1st line treatment in a non-small cell lung cancer (NSCLC) patient with epidermal growth factor receptor (*EGFR*) mutation in Korea.
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